Fenwick Represents Maze Therapeutics in Exclusive Worldwide License Agreement with Shionogi

Fenwick represented Maze Therapeutics, a biopharmaceutical company that is harnessing the power of human genetics to transform the lives of patients, with a focus on genetically informed therapies, in its exclusive worldwide license agreement with Shionogi, a global research-driven pharmaceutical company. The exclusive agreement will provide Shionogi the rights to MZE001, an investigational oral glycogen synthase 1 (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.

Under the terms of the agreement, Shionogi has acquired exclusive worldwide rights for MZE001 as well as related programs and intellectual property. Shionogi will pay an upfront fee of $150 million, and Maze will be eligible for milestone payments based on development, regulatory and commercial achievements plus tiered royalties based upon future net sales. The required 30-day waiting period outlined in United States Hart-Scott-Rodino (HSR) Act has expired, and the transaction is completed. More information about the collaboration can be obtained from Maze Therapeutics' announcement.

The Fenwick transaction team was led by technology transactions partner Jake Handy and associate Jennifer Yoon.